<DOC>
	<DOCNO>NCT00973388</DOCNO>
	<brief_summary>The purpose study evaluate effect telaprevir result electrocardiograms healthy volunteer . An electrocardiogram electric record heart . Telaprevir investigate treatment chronic hepatitis C virus infection .</brief_summary>
	<brief_title>VX-950-TiDP24-C136 - A Trial Evaluate Effect Telaprevir ( TVR ) Results Electrocardiograms ( Electric Recording Heart ) Healthy Volunteers</brief_title>
	<detailed_description>This Phase I , double-blind , double-dummy , randomize , placebo- active-controlled , 4-period crossover trial . This mean study doctor know treatment session receive active medication match placebo . Every participant receive treatment turn . The order receive treatment session determine chance , like toss coin . The purpose study evaluate effect telaprevir ( TVR ) result electrocardiograms ( electric record heart ) . Two dose regimen TVR test , i.e . 750 mg every 8 hour ( dose give patient ) 1875 mg every 8 hour ( dose high one give patient ) , administer 4 day , additional morning dose Day 5 . A single dose 400 mg moxifloxacin use positive control assess trial sensitivity . The trial population consist 44 healthy volunteer . Treatment A consist TVR 750 mg every 8 hour Days 1-4 + single 750 mg morning dose Day 5 ( 2 active TVR tablet + 3 TVR placebo tablet every 8 hour Days 1 4 single morning dose Day 5 , single morning dose moxifloxacin placebo Day 5 ) . Treatment B consist TVR 1875 mg every 8 hour Days 1 4 + single 1875 mg morning dose Day 5 ( 5 active TVR tablet every 8 hour Days 1 4 single morning dose Day 5 , single morning dose moxifloxacin placebo Day 5 ) . Treatment C consist single dose 400 mg moxifloxacin ( 5 TVR placebo tablet every 8 hour Days 1 4 single morning dose Day 5 , single morning dose active moxifloxacin Day 5 ) . Treatment D consist placebo ( 5 TVR placebo tablet every 8 hour Days 1 4 single morning dose Day 5 , single morning dose moxifloxacin placebo Day 5 ) .There washout period 8 day subsequent treatment session . Electrocardiograms ( ECGs ) record continuously 24 hour Holter monitoring ( small electrode attach chest connect small device record heart rhythm 24-hour period ) day intake study medication start Day 5 treatment session . In addition , safety monitoring , separate ECGs perform predefined time point . Samples access pharmacokinetics ( drug absorb bloodstream , distribute body eliminate body ) TVR moxifloxacin collect day intake medication start day 5 treatment session , well predose Days 2 , 3 4 treatment session . Safety tolerability evaluate throughout trial evaluate result blood- urine analysis , vital sign , physical examination , alcohol breath test assess feeling . In every treatment session , participant receive 5 oral tablet 375 mg TVR placebo every 8 hour Days 1 4 single morning dose Day 5 , single oral morning dose 400 mg moxifloxacin placebo Day 5 . In treatment session , wash-out period 8 day .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Nonsmoking least 6 month prior screen A body mass index ( BMI , weight kg divide square height meter ) 18 to30 kg/m2 , extremes included Otherwise healthy basis physical examination , medical history , electrocardiogram , vital sign result laboratory test urinalysis carry screen Consumption 2 unit alcoholic beverage per day 14 unit per week 14 day first intake study medication average five 240mL serving coffee caffeinated beverage ( e.g . tea , cola ) per day screening onwards A history drug alcohol abuse addiction within 2 year prior dose , positive test alcohol drug screen period Participation clinical study involve administration investigational drug within 2 month 5 half life ( whichever longer ) prior screen visit Donation blood significant loss blood within 3 month , donation 1 unit plasma within 7 day first dose study drug Male patient female partner plan become pregnant study within 90 day last dose study medication female patient childbearing potential pregnant planning become pregnant within 90 day completion study , use adequate contraception , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>VX-950-TiDP24-C136</keyword>
	<keyword>VX-950-C136</keyword>
	<keyword>VX-950</keyword>
	<keyword>HEPATITIS</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>ECG</keyword>
	<keyword>QT</keyword>
	<keyword>QTc</keyword>
</DOC>